trending Market Intelligence /marketintelligence/en/news-insights/trending/rulm8q5bcgqaw8krflb0aa2 content esgSubNav
In This List

Ionis Pharmaceuticals licenses potential kidney disease treatment to AstraZeneca

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Ionis Pharmaceuticals licenses potential kidney disease treatment to AstraZeneca

Ionis Pharmaceuticals Inc. licensed another one of its drugs to AstraZeneca PLC.

AZD2373, which was discovered using Ionis' antisense technology, will be investigated as a potential treatment for a genetic kidney disease.

The drug, designed to inhibit an undisclosed target and also called IONIS-AZ5-2.5Rx, will be developed and commercialized by U.K.-based AstraZeneca, which will pay Ionis $30 million in upfront plus up to $30 million in additional development and regulatory milestone payments.

Carlsbad, Calif.-based Ionis will also receive royalties on the sales of the drug, once commercialized.

Ionis entered a strategic collaboration with AstraZeneca to develop antisense therapies in 2015 for treating cardiovascular and kidney diseases.

AZD2373 is the second drug to enter development under the company's collaboration agreement with AstraZeneca.